Drug · DIN 02559137
TREMFYA
SINGLE-USE PREFILLED SYRINGE
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since July 7, 2025.
- Drug Identification Number (DIN)
- 02559137
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Guselkumab L04AC16
- Class
- Human
- Record last updated
- September 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GUSELKUMAB | 200 MG | 2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 7, 2025: NOC 35647Supplement to a New Drug Submission (SNDS) · New indication: TREMFYA /TREMFYA I.V. (guselkumab injection / guselkumab for injection) is indicated for: -the treatment of adult patients with moderately to severely active Crohn’s disease. New presentations
Other DINs named TREMFYA
- DIN 02469758 · Marketed
- DIN 02559145 · Marketed
- DIN 02566877 · Marketed
- DIN 02570890 · Approved